• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    10 Health Care Stocks With Whale Alerts In Today's Session

    2/26/24 12:35:26 PM ET
    $ABT
    $BCRX
    $CI
    $HUM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ABT alert in real time by email

    This whale alert can help traders discover the next big trading opportunities.

    Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

    Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels.

    Below are some instances of options activity happening in the Health Care sector:

    Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume
    MDRX PUT TRADE BULLISH 03/15/24 $7.50 $67.5K 17.8K 2.0K
    IBRX CALL TRADE BEARISH 01/16/26 $4.00 $39.4K 113 759
    ABT PUT TRADE BEARISH 01/17/25 $110.00 $237.5K 1.0K 563
    BCRX CALL TRADE BULLISH 01/17/25 $8.00 $52.5K 1.1K 512
    TEVA CALL SWEEP BULLISH 06/21/24 $13.00 $25.2K 81.4K 454
    TMO PUT SWEEP BEARISH 04/19/24 $500.00 $29.8K 285 333
    TGTX CALL TRADE BULLISH 01/17/25 $5.00 $36.0K 7.3K 244
    CI PUT TRADE BULLISH 05/17/24 $310.00 $34.0K 300 167
    MRK CALL SWEEP BEARISH 05/17/24 $130.00 $31.1K 8.4K 165
    HUM PUT TRADE BULLISH 06/20/25 $260.00 $52.0K 101 100

    Explanation

    These itemized elaborations have been created using the accompanying table.

    • Regarding MDRX (NASDAQ:MDRX), we observe a put option trade with bullish sentiment. It expires in 18 day(s) on March 15, 2024. Parties traded 900 contract(s) at a $7.50 strike. The total cost received by the writing party (or parties) was $67.5K, with a price of $75.0 per contract. There were 17810 open contracts at this strike prior to today, and today 2098 contract(s) were bought and sold.

    • Regarding IBRX (NASDAQ:IBRX), we observe a call option trade with bearish sentiment. It expires in 690 day(s) on January 16, 2026. Parties traded 197 contract(s) at a $4.00 strike. The total cost received by the writing party (or parties) was $39.4K, with a price of $200.0 per contract. There were 113 open contracts at this strike prior to today, and today 759 contract(s) were bought and sold.

    • Regarding ABT (NYSE:ABT), we observe a put option trade with bearish sentiment. It expires in 326 day(s) on January 17, 2025. Parties traded 500 contract(s) at a $110.00 strike. The total cost received by the writing party (or parties) was $237.5K, with a price of $475.0 per contract. There were 1063 open contracts at this strike prior to today, and today 563 contract(s) were bought and sold.

    • For BCRX (NASDAQ:BCRX), we notice a call option trade that happens to be bullish, expiring in 326 day(s) on January 17, 2025. This event was a transfer of 500 contract(s) at a $8.00 strike. The total cost received by the writing party (or parties) was $52.5K, with a price of $105.0 per contract. There were 1186 open contracts at this strike prior to today, and today 512 contract(s) were bought and sold.

    • For TEVA (NYSE:TEVA), we notice a call option sweep that happens to be bullish, expiring in 116 day(s) on June 21, 2024. This event was a transfer of 200 contract(s) at a $13.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $25.2K, with a price of $126.0 per contract. There were 81418 open contracts at this strike prior to today, and today 454 contract(s) were bought and sold.

    • For TMO (NYSE:TMO), we notice a put option sweep that happens to be bearish, expiring in 53 day(s) on April 19, 2024. This event was a transfer of 122 contract(s) at a $500.00 strike. This particular put needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $29.8K, with a price of $240.0 per contract. There were 285 open contracts at this strike prior to today, and today 333 contract(s) were bought and sold.

    • Regarding TGTX (NASDAQ:TGTX), we observe a call option trade with bullish sentiment. It expires in 326 day(s) on January 17, 2025. Parties traded 40 contract(s) at a $5.00 strike. The total cost received by the writing party (or parties) was $36.0K, with a price of $902.0 per contract. There were 7323 open contracts at this strike prior to today, and today 244 contract(s) were bought and sold.

    • Regarding CI (NYSE:CI), we observe a put option trade with bullish sentiment. It expires in 81 day(s) on May 17, 2024. Parties traded 81 contract(s) at a $310.00 strike. The total cost received by the writing party (or parties) was $34.0K, with a price of $420.0 per contract. There were 300 open contracts at this strike prior to today, and today 167 contract(s) were bought and sold.

    • For MRK (NYSE:MRK), we notice a call option sweep that happens to be bearish, expiring in 81 day(s) on May 17, 2024. This event was a transfer of 76 contract(s) at a $130.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $31.1K, with a price of $410.0 per contract. There were 8454 open contracts at this strike prior to today, and today 165 contract(s) were bought and sold.

    • Regarding HUM (NYSE:HUM), we observe a put option trade with bullish sentiment. It expires in 480 day(s) on June 20, 2025. Parties traded 50 contract(s) at a $260.00 strike. The total cost received by the writing party (or parties) was $52.0K, with a price of $1040.0 per contract. There were 101 open contracts at this strike prior to today, and today 100 contract(s) were bought and sold.

    Options Alert Terminology
    - Call Contracts: The right to buy shares as indicated in the contract.
    - Put Contracts: The right to sell shares as indicated in the contract.
    - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it.
    - Premium/Option Price: The price of the contract.

    For more information, visit our Guide to Understanding Options Alerts or read more news on unusual options activity.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ABT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABT
    $BCRX
    $CI
    $HUM

    CompanyDatePrice TargetRatingAnalyst
    ImmunityBio Inc.
    $IBRX
    3/12/2026$13.00Buy
    BTIG Research
    The Cigna Group
    $CI
    3/12/2026$358.00Mkt Perform → Outperform
    Bernstein
    Merck & Company Inc.
    $MRK
    2/25/2026$142.00Outperform
    RBC Capital Mkts
    Merck & Company Inc.
    $MRK
    2/20/2026$140.00Overweight
    Barclays
    BioCryst Pharmaceuticals Inc.
    $BCRX
    2/18/2026$17.00Outperform
    Evercore ISI
    Merck & Company Inc.
    $MRK
    2/13/2026$150.00Hold → Buy
    Deutsche Bank
    Humana Inc.
    $HUM
    2/12/2026$189.00Outperform → Sector Perform
    RBC Capital Mkts
    Humana Inc.
    $HUM
    2/2/2026$174.00Equal-Weight → Underweight
    Morgan Stanley
    More analyst ratings

    $ABT
    $BCRX
    $CI
    $HUM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research resumed coverage on ImmunityBio with a new price target

    BTIG Research resumed coverage of ImmunityBio with a rating of Buy and set a new price target of $13.00

    3/12/26 8:52:16 AM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    The Cigna Group upgraded by Bernstein with a new price target

    Bernstein upgraded The Cigna Group from Mkt Perform to Outperform and set a new price target of $358.00

    3/12/26 8:38:26 AM ET
    $CI
    Medical Specialities
    Health Care

    RBC Capital Mkts initiated coverage on Merck with a new price target

    RBC Capital Mkts initiated coverage of Merck with a rating of Outperform and set a new price target of $142.00

    2/25/26 7:52:46 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    $BCRX
    $CI
    $HUM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President, CenterWell Shetty Sanjay K bought $150,016 worth of Humana Common (810 units at $185.21), increasing direct ownership by 7% to 11,657 units (SEC Form 4)

    4 - HUMANA INC (0000049071) (Issuer)

    2/25/26 11:48:38 AM ET
    $HUM
    Medical Specialities
    Health Care

    Director Starks Daniel J bought $1,087,331 worth of Common shares without par value (10,000 units at $108.73), increasing direct ownership by 0.15% to 6,738,817 units (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    2/6/26 8:04:16 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHAIRMAN AND CEO Ford Robert B bought $2,013,967 worth of Common shares without par value (18,800 units at $107.13) (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    1/26/26 8:02:24 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    $BCRX
    $CI
    $HUM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Foard Brian

    3 - Merck & Co., Inc. (0000310158) (Issuer)

    3/12/26 1:52:51 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Meyer James claimed ownership of 5,891 shares (SEC Form 3)

    3 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

    3/10/26 4:07:46 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Chairman & CEO Casper Marc N exercised 4,000 shares at a strike of $309.63 and sold $2,059,261 worth of shares (4,000 units at $514.82) (SEC Form 4)

    4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

    3/9/26 4:39:01 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    $ABT
    $BCRX
    $CI
    $HUM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    $ABT
    $BCRX
    $CI
    $HUM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $ABT
    $BCRX
    $CI
    $HUM
    SEC Filings

    View All

    FDA Approval for BRIUMVI issued to TG THERAPEUTICS, INC

    Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (SUPPL-11) with active ingredient UBLITUXIMAB-XIIY has changed to 'Approval' on 10/30/2024. Application Category: BLA, Application Number: 761238, Application Classification:

    10/31/24 4:38:40 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    October 24, 2023 - FDA Approves New Therapy for Rare Form of Blood Cancers Called Myelodysplastic Syndromes

    For Immediate Release: October 24, 2023 Today, the U.S. Food and Drug Administration approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. This is the first targeted therapy approved for this indication. The agency also approved the Abbott RealTime

    10/24/23 3:52:17 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for BRIUMVI issued to TG THERAPEUTICS, INC

    Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (ORIG-1) with active ingredient UBLITUXIMAB has changed to 'Approval' on 12/28/2022. Application Category: BLA, Application Number: 761238, Application Classification:

    12/28/22 12:54:09 PM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Continuous Glucose Monitoring on the Rise Among Medicare Advantage Members with Type 2 Diabetes

    Study by Humana Healthcare Research and Yale School of Medicine researcher reveals significant increase in CGM usage, particularly among older adults with chronic health conditions. A new study published in the current issue of the Journal of Managed Care & Specialty Pharmacy (JMCP)—conducted by a Humana Healthcare Research team and Dr. Joseph S. Ross of the Yale School of Medicine—reveals a notable increase in the use of continuous glucose monitors (CGMs) among Medicare Advantage members with type 2 diabetes from 2021 to 2023. The study also compared the demographic and clinical characteristics of members with type 2 diabetes who used CGMs with those who did not in 2023, finding that t

    3/12/26 9:30:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management

    U.K. FreeDM2 randomized controlled trial: At four months, people using Libre technology had a 0.6% greater reduction in HbA1c and 2.5 more hours a day in the healthy range vs. fingersticks 1,2Improvements were participant-led, using real-time glucose readings to guide everyday decisionsComplementary Italian study reported similar improvements, reinforcing the value of Libre technology for this population3ABBOTT PARK, Ill., March 12, 2026 /PRNewswire/ -- Abbott (NYSE:ABT), a global healthcare leader, today announced results from the FreeDM2 randomized controlled trial (RCT) showing that people using FreeStyle Libre continuous glucose monitoring (CGM) technology had better glucose outcomes tha

    3/12/26 8:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott and Real Madrid launch nationwide effort to build the next 'Abbott Dream Team'

    Abbott, in collaboration with Real Madrid, will host free selection events combining soccer and health education to identify the second annual 'Abbott Dream Team'All participants will receive sports nutrition guidance from Abbott experts and take part in on-field development sessions led by Real Madrid coachesThe 16 selected male and female 'Abbott Dream Team' members, ages 18–19, will travel to Spain on an all‑expenses‑paid trip to train at Real Madrid's official facilitiesLearn more and register at AbbottDreamTeam.comABBOTT PARK, Ill., March 11, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) announced today the launch of the second year of the 'Abbott Dream Team,' encouraging young soccer players

    3/11/26 11:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Humana Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - HUMANA INC (0000049071) (Filer)

    3/9/26 4:22:23 PM ET
    $HUM
    Medical Specialities
    Health Care

    Abbott Laboratories filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - ABBOTT LABORATORIES (0000001800) (Filer)

    3/9/26 4:21:32 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFR14A filed by Humana Inc.

    DEFR14A - HUMANA INC (0000049071) (Filer)

    3/6/26 5:31:00 PM ET
    $HUM
    Medical Specialities
    Health Care

    $ABT
    $BCRX
    $CI
    $HUM
    Leadership Updates

    Live Leadership Updates

    View All

    The Cigna Group Announces President & COO Brian Evanko to Succeed David M. Cordani as Chief Executive Officer

    Cordani to retire as chief executive officer on July 1, 2026, and will serve as executive chair of The Cigna Group Board of DirectorsEvanko elected to the company's Board of DirectorsCompany reaffirms 2026 Financial OutlookBLOOMFIELD, Conn., March 3, 2026 /PRNewswire/ -- The Cigna Group (NYSE: CI) today announced that David M. Cordani will retire as chief executive officer effective July 1, 2026, and become executive chair of The Cigna Group's Board of Directors. Brian Evanko, current president and chief operating officer, will succeed Cordani as CEO. Throughout his tenure—inclu

    3/3/26 7:30:00 AM ET
    $CI
    Medical Specialities
    Health Care

    Merck Evolves Human Health Operating Structure to Support Portfolio Execution

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today highlighted steps to evolve the structure of its Human Health organization to ensure strong commercial execution of launches across diverse therapeutic areas, positioning the company for continued commercial success. As part of this evolution, Merck is organizing its Human Health business into an Oncology Business Unit and a Specialty, Pharma & Infectious Diseases Business Unit. This structure will enable Merck to sustain long-term leadership in oncology, while maintaining a sharp focus in support of a growing number of launches across an increasingly broad and diverse portfolio. In support of the new Human He

    2/23/26 6:45:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VINCENT COUNTRY SAFE ZONE ACTIVITY DAY PRESENTED BY CIGNA HEALTHCARE DELIVERS SUPER BOWL WEEK FUN, NFL FLAG FOOTBALL, AND WELLNESS TO OAKLAND STUDENTS

    Corporate, Nonprofit, and Philanthropic Partners Collaborated to Provide Transformative Experiences and Lasting Resources at Burckhalter Elementary School OAKLAND, Calif., Feb. 3, 2026 /PRNewswire/ -- Vincent Country Safe Zone Activity Day Presented by Cigna Healthcare, a flagship initiative of Love Thy Neighbor CDC co-founded by NFL Executive and Legend Troy Vincent, Sr. and his wife, author and chef Tommi A. Vincent, took place Tuesday, February 3, at Burckhalter Elementary School in Oakland, CA. The ninth annual event, themed Dreams Grow Here, delivered a full day of fun, food, wellness, and engaging sports activities, including NFL FLAG, for more than 200 Pre-K through fifth-grade studen

    2/3/26 8:17:00 PM ET
    $CI
    Medical Specialities
    Health Care

    $ABT
    $BCRX
    $CI
    $HUM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by TG Therapeutics Inc.

    SC 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)

    11/14/24 7:45:34 PM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Veradigm Inc.

    SC 13G - Veradigm Inc. (0001124804) (Subject)

    11/14/24 4:05:58 PM ET
    $MDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by Veradigm Inc.

    SC 13G/A - Veradigm Inc. (0001124804) (Subject)

    11/14/24 1:11:13 PM ET
    $MDRX
    EDP Services
    Technology

    $ABT
    $BCRX
    $CI
    $HUM
    Financials

    Live finance-specific insights

    View All

    AM Best Affirms Credit Ratings of The Cigna Group and Its Subsidiaries

    AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICR) of "a+" (Excellent) of the key U.S. life/health subsidiaries and Europe-based insurance companies of The Cigna Group (Cigna) (headquartered in Bloomfield, CT) (NYSE:CI). The majority of Cigna's core U.S. health insurance entities are collectively referred to as Cigna Life & Health Group. In addition, AM Best has affirmed the Long-Term ICR of "bbb+" (Good) and the Long-Term Issue Credit Ratings (Long-Term IR) of Cigna. AM Best also has affirmed the Short-Term Issue Credit Rating (Short-Term IR) of Cigna. The outlook of these Credit Ratings (ratings) is stable. (

    3/4/26 5:40:00 PM ET
    $CI
    Medical Specialities
    Health Care

    NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET

    CALABASAS, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced data from the dose-escalation portion of its Phase 1/2 clinical trial for NEO212, the Company's novel oral bio-conjugated therapy and will host a conference call to discuss the data today at 9:00am ET. NeOnc has formally notified the FDA that the Phase 1 dose-escalation portion of the NEO212-01 Phase 1/2 clinical trial has reached Maximum Tolerated Dose (MTD) at Cohort 5 (810 mg, Days 1–5, 28-day cycle) following a second

    3/4/26 8:00:00 AM ET
    $MRK
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026

    ImmunityBio, Inc. ((IBRX), today announced that it will host a live conference call at 1:30 p.m. Pacific Time on Tuesday, March 3, 2026, to provide a business update, including progress across the company's clinical trial pipeline, and to review financial results for the year ended December 31, 2025. Conference Call Details The conference call will begin at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on Tuesday, March 3, 2026. Interested parties may access the conference call through our Investor Relations website, ir.immunitybio.com, under Company — Events & Presentations. Alternatively, individuals can access the call by dialing 1-844-539-3703 or 1-412-652-1273 (internationally).

    2/27/26 7:30:00 AM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care